Abbvie Slips 1.12% on $1.54B Turnover as FDA Scrutiny Weighs on 56th-Ranked Stock

Abbvie (ABBV) closed down 1.12% on October 3, 2025, with a trading volume of $1.54 billion, ranking 56th among U.S. stocks by liquidity. The pharmaceutical giant's share price decline occurred despite a generally mixed broader market environment. Analysts noted the move reflected ongoing pressure from upcoming regulatory decisions on key product portfolios.

Recent developments highlighted uncertainty surrounding the FDA's upcoming review of AbbVie's next-generation rheumatoid arthritis therapy. While the company has maintained its 2025 guidance, market participants remain cautious about potential revenue shifts from patent expirations and competitive landscape changes. Institutional selling pressure emerged as large-cap biotech names faced profit-taking after recent gains.

To run an accurate back-test, I need to clarify a few practical details: Universe scope - which market(s) should be considered when ranking by trading volume, portfolio weighting rules for the 500-name basket, and whether to include realistic trading costs or slippage. Once parameters are defined, I can generate daily top-500 baskets and execute the back-test from January 1, 2022, to the latest close. Results can optionally be benchmarked against SPY for performance comparison.